Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

N/ACompletedNCT00683410

Wyeth is now a wholly owned subsidiary of Pfizer3,366 enrolled

Overview

To collect post-marketing information on the safety of Prevenar in Filipino patients

Study Type

OBSERVATIONAL

Enrollment

3,366

Conditions

Vaccines, Pneumococcal Conjugate Vaccine

Interventions

Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)BIOLOGICAL

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * All patients from the study center who received or will receive at least one dose of Prevenar according to the approved product indication. Exclusion Criteria: * Previously discontinued Prevenar therapy due to safety concerns.

Locations (1)

Unnamed facility

City of Muntinlupa, Philippines

Outcomes

Primary Outcomes

Number of Participants With Spontaneous Adverse Events

Time frame: 30 days post injection up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.